- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Redwood City, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor, Matched 80 mg placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 9
- States / cities
- Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 82
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Vancomycin, Metronidazole
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Aramchol meglumine
- Drug
- Lead sponsor
- Galmed Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hepatobiliary Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Sulfasalazine, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- GKT137831, Placebo oral capsule
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • Ventura, California + 17 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid (OCA), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 15
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Vancomycin, Placebo
- Drug · Other
- Lead sponsor
- Elizabeth Carey
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
- Interventions
- Erlotinib (Tarceva)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Mitomycin C, Normal saline
- Drug
- Lead sponsor
- Li, Zhiping, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- ursodeoxycholic acid (UDCA)
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
- Interventions
- Seladelpar
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis
- Interventions
- Rituximab, Lenalidomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
- Interventions
- nasal potential difference testing
- Procedure
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 9,150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2050
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- Xifaxan
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pruritus
- Interventions
- Linerixibat
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas